TY - JOUR
T1 - Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
AU - Palladini, Giovanni
AU - Campana, Carlo
AU - Klersy, Catherine
AU - Balduini, Alessandra
AU - Vadacca, Giovanbattista
AU - Perfetti, Vittorio
AU - Perlini, Stefano
AU - Obici, Laura
AU - Ascari, Edoardo
AU - D'Eril, Gianvico Melzi
AU - Moratti, Remigio
AU - Merlini, Giampaolo
PY - 2003/5/20
Y1 - 2003/5/20
N2 - Background - Brain natriuretic peptide (BNP) is a marker of ventricular dysfunction and can be used to assess prognosis in heart failure and after myocardial infarction. Heart involvement is the most important prognostic factor and causes death in almost all patients with light-chain amyloidosis (AL). We investigated the prognostic value of NT-proBNP and its utility in monitoring amyloid heart dysfunction. Methods and Results - NT-proBNP was quantified at diagnosis in 152 consecutive patients seen at the coordinating center of the Italian Amyloidosis Study Group (Pavia) from 1999 throughout 2001. Heart involvement was estimated on the basis of clinical signs, electrocardiography, and echocardiography. NT-proBNP concentrations differed in patients with (n=90, 59%) and without (n=62, 41%) heart involvement (median: 507.8 pmol/L versus 22.1 pmol/L, P= 10-7). The best cutoff for heart involvement was at 152 pmol/L (sensitivity: 93.33%, specificity: 90.16%, accuracy: 92.05%) and distinguished two groups with different survival (P
AB - Background - Brain natriuretic peptide (BNP) is a marker of ventricular dysfunction and can be used to assess prognosis in heart failure and after myocardial infarction. Heart involvement is the most important prognostic factor and causes death in almost all patients with light-chain amyloidosis (AL). We investigated the prognostic value of NT-proBNP and its utility in monitoring amyloid heart dysfunction. Methods and Results - NT-proBNP was quantified at diagnosis in 152 consecutive patients seen at the coordinating center of the Italian Amyloidosis Study Group (Pavia) from 1999 throughout 2001. Heart involvement was estimated on the basis of clinical signs, electrocardiography, and echocardiography. NT-proBNP concentrations differed in patients with (n=90, 59%) and without (n=62, 41%) heart involvement (median: 507.8 pmol/L versus 22.1 pmol/L, P= 10-7). The best cutoff for heart involvement was at 152 pmol/L (sensitivity: 93.33%, specificity: 90.16%, accuracy: 92.05%) and distinguished two groups with different survival (P
KW - Amyloid
KW - Cardiomyopathy
KW - Natriuretic peptides
KW - Prognosis
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=0038518441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038518441&partnerID=8YFLogxK
U2 - 10.1161/01.CIR.0000068314.02595.B2
DO - 10.1161/01.CIR.0000068314.02595.B2
M3 - Article
C2 - 12719281
AN - SCOPUS:0038518441
VL - 107
SP - 2440
EP - 2445
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 19
ER -